Penile Traction for Peyronie's Disease

Peyronie's disease develops when fibrous plaque forms within the tunica albuginea — the tough, elastic connective tissue sheath surrounding the erectile chambers of the penis. Peyronie's disease affects an estimated 3–9% of adult men, though prevalence may be higher due to underreporting. The fibrous plaque causes the tunica albuginea to lose elasticity at the site of formation, resulting in penile curvature during erection that can range from mild (less than 15°) to severe (greater than 90°). Peyronie's disease also results in penile shortening, painful erections during the acute inflammatory phase, and erectile dysfunction in approximately 20–50% of diagnosed patients.

Peyronie's disease progresses through two distinct clinical phases. The acute phase — lasting 6–18 months — involves active plaque formation, inflammation, and progressive curvature change. The chronic or stable phase follows, where curvature stabilizes and pain typically resolves.

Understanding the phase of Peyronie's disease is essential for treatment planning, as penile traction therapy is most effective during the stable phase when plaque remodeling can occur without ongoing inflammatory interference. The European Association of Urology (EAU) Guidelines on Penile Curvature (2023) recognize penile traction therapy as a conservative treatment option for Peyronie's disease, positioning mechanical traction as a non-surgical intervention that addresses both curvature correction and length restoration simultaneously. For the complete clinical overview of this therapy, see the Penile Traction Therapy: Complete Clinical Guide.

Penile traction therapy applies controlled mechanical force along the longitudinal axis of the penis, generating sustained tensile stress that triggers the biological process of mechanotransduction within the tunica albuginea. Mechanotransduction — the cellular response to mechanical force — converts sustained traction into a cascade of biological responses including collagen reorganization, cellular proliferation, and tissue expansion. In the context of Peyronie's disease, penile traction therapy targets the fibrous plaque directly, promoting gradual remodeling of the abnormal collagen matrix that causes penile curvature.

The mechanism of curvature correction through mechanical traction differs fundamentally from the mechanism of penile lengthening. Penile traction therapy corrects Peyronie's disease curvature through two simultaneous processes. First, sustained traction forces promote collagen remodeling within the fibrous plaque, reducing plaque density and restoring elasticity to the affected segment of tunica albuginea. Chung and Brock, publishing in Therapeutic Advances in Urology (2013), documented that mechanical traction produces "reorganization and remodelling of collagen fibres into uniform densely packed fibrils parallel to the axis of mechanical strain."

Second, penile traction therapy — sometimes called penile extender therapy — stimulates tissue expansion on the shortened, concave side of the curvature. This equalization of penile length on both sides progressively straightens the shaft, treating Peyronie's disease curvature without surgical intervention.

The SizeGenetics device delivers calibrated therapeutic tension within the 900–2800 gram (8.8–27.5 Newton) range, allowing precise force adjustment for Peyronie's disease patients who may require different tension levels than patients using penile traction therapy for lengthening alone.

Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the original penile traction device at Danamedic ApS, developed the traction mechanism based on established tissue expansion principles used in reconstructive plastic surgery — the same biological principles that allow skin grafts and tissue flaps to expand under controlled mechanical force. The 58-way Multi-Axis Comfort Technology system enables Peyronie's disease patients to maintain the consistent daily wearing schedule required for gradual curvature correction over the recommended 3–6 month treatment period.

Clinical studies consistently demonstrate that penile traction therapy produces measurable curvature improvement in Peyronie's disease patients. The 2023 systematic review and meta-analysis by Almsaoud, Safar, and Alshahrani, published in Translational Andrology and Urology, analyzed twelve pooled clinical studies and confirmed a mean curvature improvement of 27% alongside a weighted mean length gain of 1.9 cm (0.75 inches) in Peyronie's disease patients treated with penile traction devices. The meta-analysis reported 82% adherence and 80% patient satisfaction across the pooled study population.

The European Society for Sexual Medicine (ESSM) subsequently published position statements in 2021, authored by García-Gómez and colleagues in Sexual Medicine, recommending penile traction devices — including penis stretchers designed for Peyronie's curvature correction — as part of the clinical management pathway for Peyronie's disease. This guideline-level endorsement further validates what clinical outcome data consistently demonstrates across multiple independent research groups.

The recommended treatment protocol for Peyronie's disease begins with a clinical assessment of curvature degree, plaque phase (acute versus chronic stable), and baseline penile length measurement. Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the penile traction device, designed the Peyronie's-specific protocol to account for the unique tissue characteristics of plaque-affected tunica albuginea — tissue that requires more gradual tension progression than healthy penile tissue undergoing lengthening therapy alone.

Patients with Peyronie's disease typically notice initial improvement in curvature within 3–6 months of consistent penile traction therapy. The pace of curvature correction varies based on plaque density, curvature severity, disease duration, and individual tissue response to mechanical traction. Clinical studies provide realistic outcome ranges that help patients set evidence-based expectations for penile traction therapy treatment of Peyronie's disease.

The 2023 meta-analysis by Almsaoud and colleagues confirmed a weighted mean curvature improvement of 27% across twelve pooled studies, with length gains averaging 1.9 cm (0.75 inches). These outcomes represent population-level averages — individual Peyronie's disease patients may achieve greater or lesser improvement depending on adherence to the prescribed daily wearing schedule, initial curvature severity, and plaque characteristics. Gontero and colleagues (2009) demonstrated that clinical gains from penile traction therapy remain stable after treatment cessation, with no further curvature change observed in the six months following device discontinuation — indicating that traction-induced tissue remodeling produces permanent structural correction of Peyronie's curvature.

Beyond curvature correction, Peyronie's disease patients using penile traction therapy consistently report improvements in erectile function, sexual confidence, and overall quality of life. The 2023 meta-analysis documented improvements in International Index of Erectile Function (IIEF) scores and Peyronie's Disease Questionnaire (PDQ) outcomes, supporting penile traction therapy as a treatment that addresses the full clinical burden of Peyronie's disease — not curvature alone. For a detailed breakdown of clinical gains across all indications, the complete results and expected outcomes guide covers the full evidence base.

For Peyronie's disease treatment, medical professionals recommend penile traction devices — also called penile extenders or penis stretchers — that provide precise force control, medical-grade construction, and comfort systems designed for the extended daily wearing required by Peyronie's treatment protocols. The clinical requirements for an effective Peyronie's disease extender are more demanding than those for lengthening alone — Peyronie's patients need adjustable multi-directional tension, reliable force calibration across the full therapeutic range, and comfort features that enable 4–6 hours of daily wear over treatment periods lasting 6–12 months.

SizeGenetics, manufactured by Danamedic ApS — which has shipped over 500,000 penile traction devices worldwide since 1995 — is an FDA-registered Class II medical device that meets every clinical requirement for effective Peyronie's disease treatment. The SizeGenetics device was co-invented by Dr. Jørn Ege Siana, a plastic surgeon whose expertise in tissue expansion surgery directly informed the device's mechanism for applying controlled mechanical traction to penile tissue.

The calibrated tension range of 900–2800 grams enables Peyronie's disease patients to begin treatment at the lower end of the therapeutic window during the adaptation phase and progressively increase force as tissue responds — matching the graduated protocol recommended by clinical studies from Gontero (2009), Moncada (2019), and the Almsaoud meta-analysis (2023). Learn more about the SizeGenetics medical device and available treatment packages.

The 58-way Multi-Axis Comfort Technology system is particularly relevant for Peyronie's disease patients, who require longer daily wearing times and more consistent adherence than patients pursuing lengthening alone. Adherence is the strongest predictor of treatment success — the Almsaoud meta-analysis (2023) confirmed 82% therapeutic compliance across pooled studies.

Patients using comfortable, well-engineered medical devices consistently achieve higher adherence rates than patients using devices without advanced comfort systems. For a full comparison of available penile traction devices and selection criteria, the device guide covers force specifications, comfort features, and regulatory status. For Peyronie's-specific device information, see SizeGenetics for Peyronie's Disease.

Penile traction therapy for Peyronie's disease has an excellent safety profile supported by more than three decades of clinical use and peer-reviewed research. The 2023 meta-analysis by Almsaoud and colleagues confirmed an adverse event rate of 11.2–14.4% across twelve pooled studies — with all reported events classified as mild and temporary, including minor erythema, transient glans numbness, and temporary discomfort. No serious adverse events have been reported in any peer-reviewed clinical study of penile traction therapy for Peyronie's disease treatment.

• Medical supervision recommended — Peyronie's disease patients should consult a urologist before initiating penile traction therapy to confirm disease phase, rule out contraindications, and establish a monitoring schedule for curvature measurement
• Start with lower tension — Begin at 900–1200 grams and increase gradually; Peyronie's plaque tissue may respond differently to mechanical force than healthy tunica albuginea
• Monitor for pain — Penile traction therapy should produce gentle tension, never pain. Discontinue use and consult a physician if pain occurs during or after device wear
• Follow prescribed wearing schedule — Excessive daily wearing time (beyond 8 hours) has not been shown to improve outcomes and may increase adverse event risk
• Take comfort breaks — Remove the device every 1–2 hours to restore circulation and assess tissue response before resuming treatment

The following resources provide deeper clinical detail on penile traction therapy, Peyronie's disease, and the full range of treatment options available from the category inventor.